Novartis Galvus shows efficacy in type 2 diabetes trial
The study also demonstrated that vildagliptin added to current therapy resulted in significant improvements in glycemic control. The data showed that the overall safety and tolerability of vildagliptin
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.